PMID- 35293663
OWN - NLM
STAT- MEDLINE
DCOM- 20220725
LR  - 20220725
IS  - 1095-8355 (Electronic)
IS  - 1065-6995 (Linking)
VI  - 46
IP  - 8
DP  - 2022 Aug
TI  - OSI-027 inhibits the tumorigenesis of colon cancer through mediation of 
      c-Myc/FOXO3a/PUMA axis.
PG  - 1204-1214
LID - 10.1002/cbin.11792 [doi]
AB  - Colon cancer is a gastrointestinal malignancy that is one of the leading causes 
      of tumor-associated deaths. It has been reported that the mammalian target of 
      rapamycin (mTOR) can lead to the progression of colon cancer. However, the 
      mechanism by which mTOR inhibitor (OSI-027) mediates the tumorigenesis of colon 
      cancer remains largely unknown. Cell function of colon cancer was investigated by 
      cell counting kit-8 flow cytometry and terminal deoxynucleotidyl transferase dUTP 
      nick end labeling staining. In addition, quantitative real-time polymerase chain 
      reaction and Western blot were used to investigate the mechanism underlying the 
      function of OSI-027 in colon cancer. OSI-027 dose-dependently reduced colon 
      cancer cell viability by inducing cell apoptosis. In addition, OSI-027 induced 
      the apoptosis of colon cancer cells via upregulation of PUMA. OSI-027 promoted 
      the expression of PUMA by activation of forkhead box protein O3a (FOXO3a), and 
      c-Myc knockdown partially increased FOXO3a and PUMA levels. Moreover, OSI-027 
      attenuated the tumor growth of colon cancer through the mediation of the 
      mTOR/c-Myc/FOXO3a axis. OSI-027 attenuates colon cancer progression through the 
      mediation of the c-Myc/FOXO3a/PUMA axis. Thereby, this study might shed new 
      insights on exploring the strategies against colon cancer.
CI  - (c) 2022 International Federation for Cell Biology.
FAU - Lou, Jie
AU  - Lou J
AD  - Department of Gastroenterology, Shanghai Tenth People's Hospital, School of 
      Medicine, Tongji University, Shanghai, China.
AD  - Department of Gastroenterology, HwaMei Hospital, University of Chinese Academy of 
      Sciences, Ningbo, Zhejiang, China.
FAU - Lv, Jian-Xin
AU  - Lv JX
AD  - Department of Gastroenterology, HwaMei Hospital, University of Chinese Academy of 
      Sciences, Ningbo, Zhejiang, China.
FAU - Zhang, You-Ping
AU  - Zhang YP
AD  - Department of Gastroenterology, HwaMei Hospital, University of Chinese Academy of 
      Sciences, Ningbo, Zhejiang, China.
FAU - Liu, Zhan-Ju
AU  - Liu ZJ
AUID- ORCID: 0000-0003-2326-2268
AD  - Department of Gastroenterology, Shanghai Tenth People's Hospital, School of 
      Medicine, Tongji University, Shanghai, China.
LA  - eng
GR  - 2019A610336/Ningbo Natural Science Foundation, China/
PT  - Journal Article
DEP - 20220608
PL  - England
TA  - Cell Biol Int
JT  - Cell biology international
JID - 9307129
RN  - 0 (Apoptosis Regulatory Proteins)
RN  - 0 (Forkhead Box Protein O3)
RN  - 0 (Forkhead Transcription Factors)
RN  - 0 (Imidazoles)
RN  - 0 (OSI 027)
RN  - 0 (Proto-Oncogene Proteins)
RN  - 0 (Triazines)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Apoptosis
MH  - *Apoptosis Regulatory Proteins/metabolism
MH  - Carcinogenesis
MH  - Cell Line, Tumor
MH  - Cell Transformation, Neoplastic
MH  - *Colonic Neoplasms/metabolism
MH  - Forkhead Box Protein O3/metabolism
MH  - Forkhead Transcription Factors/metabolism
MH  - Humans
MH  - Imidazoles
MH  - Proto-Oncogene Proteins/metabolism
MH  - Proto-Oncogene Proteins c-akt/metabolism
MH  - TOR Serine-Threonine Kinases
MH  - Triazines
OTO - NOTNLM
OT  - OSI-027
OT  - PUMA
OT  - c-Myc/FOXO3a
OT  - colon cancer
EDAT- 2022/03/17 06:00
MHDA- 2022/07/26 06:00
CRDT- 2022/03/16 08:45
PHST- 2022/01/16 00:00 [revised]
PHST- 2021/10/22 00:00 [received]
PHST- 2022/03/13 00:00 [accepted]
PHST- 2022/03/17 06:00 [pubmed]
PHST- 2022/07/26 06:00 [medline]
PHST- 2022/03/16 08:45 [entrez]
AID - 10.1002/cbin.11792 [doi]
PST - ppublish
SO  - Cell Biol Int. 2022 Aug;46(8):1204-1214. doi: 10.1002/cbin.11792. Epub 2022 Jun 
      8.